Ning Zhang

Dr. Ning Zhang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
MWMengmeng Wang
Mengmeng Wang
TTTianqi Teng
Tianqi Teng
NZNan Zhang
Nan Zhang
JXJiachao Xu
Jiachao Xu
ZDZihan Dong
Zihan Dong
HYHaichu Yu
Haichu Yu
The direct association between elevated levels of the triglyceride-glucose index (TyG index) and its derived metrics and the risk of new-onset hypertension in prehypertensive populations remains unclear. The study systematically evaluated the link between the TyG index and its related indicators with new-onset hypertension by integrating cohort study methods with Mendelian randomization (MR) analysis. A total of 2,815 prehypertensive participants from the 2011 CHARLS database were included, of whom 877 (31.15%) progressed to new-onset hypertension by 2015. TyG-Waist-to-Height Ratio (TyG-WHtR), TyG-Body Mass Index (TyG-BMI), TyG-Waist Circumference (TyG-WC), and the TyG index were calculated. Logistic regression, restricted cubic spline (RCS) curves, subgroup analyses, and interaction tests were performed to assess the associations. Bayesian weighted MR (BWMR) was further used to validate causal relationships. Multivariable regression analysis revealed that each unit increase in the TyG index was associated with a 45% higher risk of new-onset hypertension (odds ratio [OR]: 1.45, 95% confidence intervals [CI] 1.24–1.70, P < 0.001), while TyG-WHtR showed a 42% increased risk (OR: 1.42, 95% CI 1.26–1.60, P < 0.001). Categorizing the TyG and its derived metrics by quartiles demonstrated that higher quartiles (Q3 and Q4) were significantly linked to an elevated risk of new-onset hypertension across all models (P < 0.001). RCS models indicated significant positive linear relationships between the TyG index and TyG-WC with new-onset hypertension (P for overall < 0.001, P for nonlinearity = 0.844 and 0.165, respectively), whereas TyG-WHtR and TyG-BMI exhibited significant positive nonlinear relationships (P for overall < 0.001, P for nonlinearity = 0.001 and 0.046, respectively). Subgroup analyses highlighted stronger associations among individuals aged ≥ 70 years, those who were widowed, had cardiovascular disease, or reported a life satisfaction score of 2 (P < 0.05, P for interaction < 0.05). BWMR analysis confirmed a significant causal relationship between genetically elevated TyG index levels and an increased risk of new-onset hypertension (P < 0.05). Our study reveals a significant link between the TyG index and its related indicators with new-onset hypertension in prehypertensive populations. Causal analysis using BWMR confirmed that genetically elevated TyG index levels increase the risk of new-onset hypertension. These results highlight the importance of monitoring TyG-related indices for early detection and intervention in high-risk individuals, aiding in the prevention of hypertension progression.

24 July 2024 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MWMengmeng Wang
Mengmeng Wang
DMDegang Mo
Degang Mo
CZChi Zhou
Chi Zhou
WZWenqiang Zhang
Wenqiang Zhang
RCRui Chen
Rui Chen
HYHaichu Yu
Haichu Yu

6 July 2020 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
WWWen-Ying Wei
Wen-Ying Wei
QZQing Zhao
Qing Zhao
WZWen-Zhong Zhang
Wen-Zhong Zhang
MWMao-Jing Wang
Mao-Jing Wang
YLYan Li
Yan Li
NZNing Zhang
Ning Zhang

28 July 2024 in Heliyon
Verified
Journal Article
Open access
MWMengmeng Wang
Mengmeng Wang
DMDegang Mo
Degang Mo
NZNing Zhang
Ning Zhang
HYHaichu Yu
Haichu Yu
Diabetic cardiomyopathy (DCM) is a common complication of diabetes, and its pathogenesis remains elusive. Ferroptosis, a process dependent on iron-mediated cell death, plays a crucial role in DCM via disrupted iron metabolism, lipid peroxidation, and weakened antioxidant defenses. Hyperglycemia, oxidative stress, and inflammation may exacerbate ferroptosis in diabetes. This review emphasizes the interaction between cardiac fibroblasts and cardiomyocytes in DCM, influencing ferroptosis occurrence. By exploring ferroptosis modulation for potential therapeutic targets, this article offers a fresh perspective on DCM treatment. The study systematically covers the interplay, mechanisms, and targeted drugs linked to ferroptosis in DCM development.

7 November 2025 in Circulation Research
Verified
Journal Article
Closed access
XLXin Liu
Xin Liu
PZPeng Zhang
Peng Zhang
ZLZhexun Lian
Zhexun Lian
HYHaichu Yu
Haichu Yu
YLYonghong Li
Yonghong Li
JGJunbo Ge
Junbo Ge
BACKGROUND: The homeostatic chemokine CCL21 (C-C motif chemokine ligand 21) is abnormally elevated in coronary artery disease. Plasma CCL21 levels have been found to be independently associated with adverse outcomes after acute coronary syndrome. However, the specific effects of CCL21 on coronary artery disease–associated platelet activation and thrombosis remain poorly understood. METHODS: We examined the effects of CCL21 on platelet activation, spreading, clot retraction, in vitro shear stress–induced thrombus formation, in vivo arterial thrombus formation, middle cerebral artery occlusion–induced brain injury, and myocardial ischemia-reperfusion injury. We also investigated the underlying mechanisms and the therapeutic impacts of a CCL21 antibody on platelet activation and in vivo thrombosis in atherosclerosis. RESULTS: CCL21 potentiated agonist-induced platelet activation, including aggregation, dense granule release, P-selectin exposure, integrin αIIbβ3 activation, spreading, and clot retraction. Furthermore, CCL21 enhanced in vivo thrombosis, whole blood thrombus formation, and middle cerebral artery occlusion–induced brain injury. Mechanistically, CCL21 binds to platelet CCR7 (C-C motif chemokine receptor 7), a G-protein–coupled receptor previously unreported in platelets, activating Gi (inhibitory G protein) and G13 signaling pathways to enhance platelet activation. A CCL21 antibody attenuated platelet activation and inhibited in vivo thrombosis in patients with coronary artery disease and atherosclerotic ApoE −/− mice. In addition, this antibody mitigated microvascular thrombosis, safeguarding the hearts of atherosclerotic ApoE − / − mice from severe ischemia-reperfusion injury. CONCLUSIONS: CCL21 enhances platelet activation and atherothrombosis by binding to platelet CCR7 and thus activating downstream Gi and G13 signaling pathways. A CCL21 antibody can counteract these effects in the context of coronary artery disease, supporting its potential as a preventive therapy for thrombotic complications.

15 August 2025 in International Journal of Cardiology
Verified
Journal Article
Closed access
MWMengmeng Wang
Mengmeng Wang
TTTianqi Teng
Tianqi Teng
DMDegang Mo
Degang Mo
NZNan Zhang
Nan Zhang
RCRui Chen
Rui Chen
HYHaichu Yu
Haichu Yu